Comerica Bank Dynavax Technologies Corp Transaction History

Comerica Bank

$25.9 Billion
Q3 2025

A detailed history of Comerica Bank transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Comerica Bank holds 27,028 shares of DVAX stock, worth $298,929. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,028

Previous 33,906 20.29%

Holding current value

$298,929

Previous $336,000 20.24%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$9.36 - $11.36 $64,378 - $78,134	-6,878 Reduced 20.29%	27,028 $268,000
Q2 2025 Aug 13, 2025	SELL	$9.4 - $12.87 $49,538 - $67,824	-5,270 Reduced 13.45%	33,906 $336,000
Q1 2025 May 14, 2025	SELL	$12.39 - $14.4 $250,724 - $291,398	-20,236 Reduced 34.06%	39,176 $508,000
Q4 2024 Feb 14, 2025	BUY	$10.28 - $13.66 $234,702 - $311,871	22,831 Added 62.41%	59,412 $758,000
Q3 2024 Nov 14, 2024	SELL	$10.05 - $11.61 $44,511 - $51,420	-4,429 Reduced 10.8%	36,581 $407,000

Q2 2024 Aug 15, 2024	SELL	$10.73 - $12.58 $54,959 - $64,434	-5,122 Reduced 11.1%	41,010 $460,000
Q1 2024 May 15, 2024	SELL	$11.7 - $14.98 $83,877 - $107,391	-7,169 Reduced 13.45%	46,132 $572,000
Q4 2023 Feb 14, 2024	SELL	$13.09 - $14.98 $3,887 - $4,449	-297 Reduced 0.55%	53,301 $745,000
Q3 2023 Nov 21, 2023	BUY	$12.64 - $14.99 $677,478 - $803,434	53,598 New	53,598 $791,000
Q2 2023 Aug 22, 2023	SELL	$9.85 - $13.17 $642,761 - $859,408	-65,255 Closed	0 $0
Q4 2022 Jan 26, 2023	SELL	$10.27 - $13.29 $202,832 - $262,477	-19,750 Reduced 23.23%	65,255 $0
Q3 2022 Oct 28, 2022	SELL	$9.93 - $17.44 $97,860 - $171,871	-9,855 Reduced 10.39%	85,005 $961,000
Q2 2022 Aug 02, 2022	BUY	$7.45 - $12.83 $706,707 - $1.22 Million	94,860 New	94,860 $1.38 Million

Others Institutions Holding DVAX

# of Institutions

303

Shares Held

120M

Call Options Held

293K

Put Options Held

311K

View Full List

About DYNAVAX TECHNOLOGIES CORP

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.4B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

More about DVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.

Account